Evolving challenges in hepatic fibrosis (original) (raw)

• Friedman, S. L. Mechanisms of hepatic fibrosis and therapeutic implications. Nat. Clin. Pract. Gastroenterol. Hepatol. 1, 98–105 (2004).
  PubMed Google Scholar
• Mitchell, A. E., Colvin, H. M. & Palmer Beasley, R. Institute of Medicine recommendations for the prevention and control of hepatitis B and C. Hepatology 51, 729–733 (2010).
  PubMed Google Scholar
• Davis, G. L., Alter, M. J., El-Serag, H., Poynard, T. & Jennings, L. W. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 138, 513–521, 521 e1–6 (2010).
  PubMed Google Scholar
• Lim, Y. S. & Kim, W. R. The global impact of hepatic fibrosis and end-stage liver disease. Clin. Liver Dis. 12, 733–746 (2008).
  PubMed Google Scholar
• Cheung, O. & Sanyal, A. J. Recent advances in nonalcoholic fatty liver disease. Curr. Opin. Gastroenterol. 25, 230–237 (2009).
  PubMed Google Scholar
• Bugianesi, E. Non-alcoholic steatohepatitis and cancer. Clin. Liver Dis. 11, 191–207 (2007).
  CAS PubMed Google Scholar
• Hashizume, H. et al. Primary liver cancers with nonalcoholic steatohepatitis. Eur. J. Gastroenterol. Hepatol. 19, 827–834 (2007).
  PubMed Google Scholar
• Jemal, A. et al. Cancer statistics, 2009. CA Cancer J. Clin. 59, 225–249 (2009).
  PubMed Google Scholar
• Friedman, S. L. Mechanisms of hepatic fibrogenesis. Gastroenterology 134, 1655–1669 (2008).
  CAS PubMed Google Scholar
• Schuppan, D. & Afdhal, N. H. Liver cirrhosis. Lancet 371, 838–851 (2008).
  CAS PubMed Central PubMed Google Scholar
• Jiao, J., Friedman, S. L. & Aloman, C. Hepatic fibrosis. Curr. Opin. Gastroenterol. 25, 223–229 (2009).
  PubMed Central PubMed Google Scholar
• Parola, M. & Pinzani, M. Hepatic wound repair. Fibrogenesis Tissue Repair 2, 4 (2009).
  PubMed Central PubMed Google Scholar
• Henderson, N. C. & Iredale, J. P. Liver fibrosis: cellular mechanisms of progression and resolution. Clin. Sci. (Lond.) 112, 265–280 (2007).
  CAS Google Scholar
• Baertschiger, R. M. et al. Fibrogenic potential of human multipotent mesenchymal stromal cells in injured liver. PLOS ONE 4, e6657 (2009).
  PubMed Central PubMed Google Scholar
• Miyata, E. et al. Hematopoietic origin of hepatic stellate cells in the adult liver. Blood 111, 2427–2435 (2008).
  CAS PubMed Google Scholar
• Russo, F. P. et al. The bone marrow functionally contributes to liver fibrosis. Gastroenterology 130, 1807–1821 (2006).
  PubMed Google Scholar
• Forbes, S. J. et al. A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. Gastroenterology 126, 955–963 (2004).
  PubMed Google Scholar
• Fujimiya, T. et al. Pathological roles of bone-marrow-derived stellate cells in a mouse model of alcohol-induced fatty liver. Am. J. Physiol. Gastrointest. Liver Physiol. 297, G974–G980 (2009).
  PubMed Google Scholar
• Strieter, R. M. & Mehrad, B. New mechanisms of pulmonary fibrosis. Chest 136, 1364–1370 (2009).
  PubMed Central PubMed Google Scholar
• Grande, M. T. & Lopez-Novoa, J. M. Fibroblast activation and myofibroblast generation in obstructive nephropathy. Nat. Rev. Nephrol. 5, 319–328 (2009).
  CAS PubMed Google Scholar
• Kisseleva, T. et al. Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. J. Hepatol. 45, 429–438 (2006).
  CAS PubMed Google Scholar
• Higashiyama, R. et al. Negligible contribution of bone marrow-derived cells to collagen production during hepatic fibrogenesis in mice. Gastroenterology 137, 1459–1466 (2009).
  CAS PubMed Google Scholar
• Kalluri, R. & Neilson, E. G. Epithelial-mesenchymal transition and its implications for fibrosis. J. Clin. Invest. 112, 1776–1784 (2003).
  CAS PubMed Central PubMed Google Scholar
• Lin, S. L., Kisseleva, T., Brenner, D. A. & Duffield, J. S. Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am. J. Pathol. 173, 1617–1627 (2008).
  CAS PubMed Central PubMed Google Scholar
• Humphreys, B. D. et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am. J. Pathol. 176, 85–97 (2010).
  CAS PubMed Central PubMed Google Scholar
• Zeisberg, M. et al. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J. Biol. Chem. 282, 23337–23347 (2007).
  CAS PubMed Google Scholar
• Omenetti, A. et al. Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans. J. Clin. Invest. 118, 3331–3342 (2008).
  CAS PubMed Central PubMed Google Scholar
• Omenetti, A. et al. Repair-related activation of hedgehog signaling promotes cholangiocyte chemokine production. Hepatology 50, 518–527 (2009).
  CAS PubMed Google Scholar
• Choi, S. S. & Diehl, A. M. Epithelial-to-mesenchymal transitions in the liver. Hepatology 50, 2007–2013 (2009).
  CAS PubMed Google Scholar
• Taura, K. et al. Hepatocytes do not undergo epithelial-mesenchymal transition in liver fibrosis in mice. Hepatology 51, 1027–1036 (2010).
  PubMed Google Scholar
• Wells, R. G. The epithelial-to-mesenchymal transition in liver fibrosis: here today, gone tomorrow? Hepatology 51, 737–740 (2010).
  CAS PubMed Google Scholar
• Kordes, C. et al. CD133+ hepatic stellate cells are progenitor cells. Biochem. Biophys. Res. Commun. 352, 410–417 (2007).
  CAS PubMed Google Scholar
• Sawitza, I., Kordes, C., Reister, S. & Haussinger, D. The niche of stellate cells within rat liver. Hepatology 50, 1617–1624 (2009).
  CAS PubMed Google Scholar
• Roskams, T. Relationships among stellate cell activation, progenitor cells, and hepatic regeneration. Clin. Liver Dis. 12, 853–860 (2008).
  PubMed Google Scholar
• Seki, E. et al. CCR1 and CCR5 promote hepatic fibrosis in mice. J. Clin. Invest. 119, 1858–1870 (2009).
  CAS PubMed Central PubMed Google Scholar
• Seki, E. et al. CCR2 promotes hepatic fibrosis in mice. Hepatology 50, 185–197 (2009).
  CAS PubMed Google Scholar
• Pinzani, M. & Marra, F. Cytokine receptors and signaling in hepatic stellate cells. Semin. Liver Dis. 21, 397–416 (2001).
  CAS PubMed Google Scholar
• Wasmuth, H. E. et al. Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. Gastroenterology 137, 309–319, 319 e1–3 (2009).
  CAS PubMed Google Scholar
• Marra, F. & Bertolani, C. Adipokines in liver diseases. Hepatology 50, 957–969 (2009).
  CAS PubMed Google Scholar
• Ikejima, K., Okumura, K., Kon, K., Takei, Y. & Sato, N. Role of adipocytokines in hepatic fibrogenesis. J. Gastroenterol. Hepatol. 22 (Suppl. 1), S87–S92 (2007).
  CAS PubMed Google Scholar
• Ding, X. et al. The roles of leptin and adiponectin: a novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology. Am. J. Pathol. 166, 1655–1669 (2005).
  CAS PubMed Central PubMed Google Scholar
• Ebrahimkhani, M. R., Elsharkawy, A. M. & Mann, D. A. Wound healing and local neuroendocrine regulation in the injured liver. Expert Rev. Mol. Med. 10, e11 (2008).
  PubMed Google Scholar
• Teixeira-Clerc, F. et al. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat. Med. 12, 671–676 (2006).
  CAS PubMed Google Scholar
• Munoz-Luque, J. et al. Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. J. Pharmacol. Exp. Ther. 324, 475–483 (2008).
  CAS PubMed Google Scholar
• Deveaux, V. et al. Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis. PLoS ONE 4, e5844 (2009).
  PubMed Central PubMed Google Scholar
• Passino, M. A., Adams, R. A., Sikorski, S. L. & Akassoglou, K. Regulation of hepatic stellate cell differentiation by the neurotrophin receptor p75NTR. Science 315, 1853–1856 (2007).
  CAS PubMed Google Scholar
• Kendall, T. J. et al. p75 Neurotrophin receptor signaling regulates hepatic myofibroblast proliferation and apoptosis in recovery from rodent liver fibrosis. Hepatology 49, 901–910 (2009).
  CAS PubMed Google Scholar
• Fernandez, M. et al. Angiogenesis in liver disease. J. Hepatol. 50, 604–620 (2009).
  CAS PubMed Google Scholar
• Novo, E. & Parola, M. Redox mechanisms in hepatic chronic wound healing and fibrogenesis. Fibrogenesis Tissue Repair 1, 5 (2008).
  PubMed Central PubMed Google Scholar
• De Minicis, S. & Brenner, D. A. NOX in liver fibrosis. Arch. Biochem. Biophys. 462, 266–272 (2007).
  CAS PubMed Central PubMed Google Scholar
• Zhan, S. S. et al. Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo. Hepatology 43, 435–443 (2006).
  CAS PubMed Google Scholar
• Colmenero, J. et al. Effects of losartan on hepatic expression of non-phagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C. Am. J. Physiol. Gastrointest. Liver Physiol. 297, G726–G734 (2009).
  CAS PubMed Central PubMed Google Scholar
• Moreno, M. et al. Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats. Hepatology 51, 942–952 (2009).
  Google Scholar
• Sanyal, A. J. et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 362, 1–5 (2010).
  Google Scholar
• Sanyal, A. A randomized controlled trial of pioglitazone or vitamin E for nonalcoholic steatohepatitis (PIVENS) [abstract]. Hepatology 50, 90A (2009).
  Google Scholar
• Wells, R. G. The role of matrix stiffness in regulating cell behavior. Hepatology 47, 1394–1400 (2008).
  CAS PubMed Google Scholar
• Georges, P. C. et al. Increased stiffness of the rat liver precedes matrix deposition: implications for fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 293, G1147–G1154 (2007).
  CAS PubMed Google Scholar
• Park, O. et al. Diverse roles of invariant natural killer T cells in liver injury and fibrosis induced by carbon tetrachloride. Hepatology 49, 1683–1694 (2009).
  CAS PubMed Google Scholar
• Gao, B., Radaeva, S. & Park, O. Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases. J. Leukoc. Biol. 86, 513–528 (2009).
  CAS PubMed Central PubMed Google Scholar
• Notas, G., Kisseleva, T. & Brenner, D. NK and NKT cells in liver injury and fibrosis. Clin. Immunol. 130, 16–26 (2009).
  CAS PubMed Google Scholar
• Connolly, M. K. et al. In liver fibrosis, dendritic cells govern hepatic inflammation in mice via TNF-alpha. J. Clin. Invest. 119, 3213–3225 (2009).
  CAS PubMed Central PubMed Google Scholar
• Seki, E. et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat. Med. 13, 1324–1332 (2007).
  CAS PubMed Google Scholar
• Seki, E. & Brenner, D. A. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology 48, 322–335 (2008).
  CAS PubMed Google Scholar
• Guo, J. et al. Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of Toll-like receptor 4 to hepatic stellate cell responses. Hepatology 49, 960–968 (2009).
  CAS PubMed Google Scholar
• Mencin, A., Kluwe, J. & Schwabe, R. F. Toll-like receptors as targets in chronic liver diseases. Gut 58, 704–720 (2009).
  CAS PubMed Google Scholar
• Chakraborty, J. B. & Mann, D. A. NF-kappaB signalling: embracing complexity to achieve translation. J. Hepatol. 52, 285–291 (2010).
  CAS PubMed Google Scholar
• Watanabe, A. et al. Inflammasome-mediated regulation of hepatic stellate cells. Am. J. Physiol. Gastrointest. Liver Physiol. 296, G1248–G1257 (2009).
  CAS PubMed Central PubMed Google Scholar
• Muhanna, N. et al. Activation of hepatic stellate cells after phagocytosis of lymphocytes: a novel pathway of fibrogenesis. Hepatology 48, 963–977 (2008).
  CAS PubMed Google Scholar
• Holt, A. P. et al. Liver myofibroblasts regulate infiltration and positioning of lymphocytes in human liver. Gastroenterology 136, 705–714 (2009).
  CAS PubMed Google Scholar
• Mann, J. & Mann, D. A. Transcriptional regulation of hepatic stellate cells. Adv. Drug Deliv. Rev. 61, 497–512 (2009).
  CAS PubMed Google Scholar
• Mann, J. et al. Regulation of myofibroblast transdifferentiation by DNA methylation and MeCP2: implications for wound healing and fibrogenesis. Cell Death Differ. 14, 275–285 (2007).
  CAS PubMed Google Scholar
• Mann, J. et al. MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis. Gastroenterology 138, 705–714, 714 e1–4 (2010).
  CAS PubMed Google Scholar
• Fritz, D. & Stefanovic, B. RNA-binding protein RBMS3 is expressed in activated hepatic stellate cells and liver fibrosis and increases expression of transcription factor Prx1. J. Mol. Biol. 371, 585–595 (2007).
  CAS PubMed Central PubMed Google Scholar
• Guo, C. J., Pan, Q., Li, D. G., Sun, H. & Liu, B. W. miR-15b and miR-16 are implicated in activation of the rat hepatic stellate cell: an essential role for apoptosis. J. Hepatol. 50, 766–778 (2009).
  CAS PubMed Google Scholar
• Venugopal, S. K. et al. Liver fibrosis causes down-regulation of miRNA-150 and miRNA-194 in hepatic stellate cells and their over-expression causes decreased stellate cell activation. Am. J. Physiol. Gastrointest. Liver Physiol. 298, G101–G106 (2009).
  PubMed Central PubMed Google Scholar
• Oakley, F. et al. Angiotensin II activates I kappaB kinase phosphorylation of RelA at Ser 536 to promote myofibroblast survival and liver fibrosis. Gastroenterology 136, 2334–2344 e1 (2009).
  CAS PubMed Google Scholar
• Buck, M. & Chojkier, M. A ribosomal S-6 kinase-mediated signal to C/EBP-beta is critical for the development of liver fibrosis. PLoS ONE 2, e1372 (2007).
  PubMed Central PubMed Google Scholar
• Friedman, S. L. & Bansal, M. B. Reversal of hepatic fibrosis—fact or fantasy? Hepatology 43, S82–S88 (2006).
  CAS PubMed Google Scholar
• Mallet, V. et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann. Intern. Med. 149, 399–403 (2008).
  PubMed Google Scholar
• Gonzalez, S. A. et al. Inverse association between hepatic stellate cell apoptosis and fibrosis in chronic hepatitis C virus infection. J. Viral Hepat. 16, 141–148 (2009).
  CAS PubMed Google Scholar
• Oakley, F. et al. Inhibition of inhibitor of kappaB kinases stimulates hepatic stellate cell apoptosis and accelerated recovery from rat liver fibrosis. Gastroenterology 128, 108–120 (2005).
  CAS PubMed Google Scholar
• Jiang, J. X., Mikami, K., Venugopal, S., Li, Y. & Torok, N. J. Apoptotic body engulfment by hepatic stellate cells promotes their survival by the JAK/STAT and Akt/NF-kappaB-dependent pathways. J. Hepatol. 51, 139–148 (2009).
  CAS PubMed Central PubMed Google Scholar
• Krizhanovsky, V. et al. Senescence of activated stellate cells limits liver fibrosis. Cell 134, 657–667 (2008).
  CAS PubMed Central PubMed Google Scholar
• Regev, A. et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am. J. Gastroenterol. 97, 2614–2618 (2002).
  PubMed Google Scholar
• Ratziu, V. et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128, 1898–1906 (2005).
  PubMed Google Scholar
• Bedossa, P., Dargere, D. & Paradis, V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 38, 1449–1457 (2003).
  PubMed Google Scholar
• Goodman, Z. D. et al. Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial. Hepatology 50, 1738–1749 (2009).
  PubMed Google Scholar
• Calvaruso, V. et al. Computer-assisted image analysis of liver collagen: relationship to Ishak scoring and hepatic venous pressure gradient. Hepatology 49, 1236–1244 (2009).
  PubMed Google Scholar
• Everhart, J. E. et al. Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology 51, 585–594 (2010).
  PubMed Google Scholar
• Castera, L. Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. J. Viral Hepat. 16, 300–314 (2009).
  PubMed Google Scholar
• Vizzutti, F., Arena, U., Marra, F. & Pinzani, M. Elastography for the non-invasive assessment of liver disease: limitations and future developments. Gut 58, 157–160 (2009).
  PubMed Google Scholar
• Pinzani, M., Vizzutti, F., Arena, U. & Marra, F. Technology Insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography. Nat. Clin. Pract. Gastroenterol. Hepatol. 5, 95–106 (2008).
  CAS PubMed Google Scholar
• Arena, U. et al. Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology 47, 380–384 (2008).
  CAS PubMed Google Scholar
• Vigano, M. et al. Transient elastography assessment of the liver stiffness dynamics during acute hepatitis B. Eur. J. Gastroenterol. Hepatol. 22, 180–184 (2009).
  Google Scholar
• Carrion, J. A. et al. Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation. Hepatology 51, 23–34 (2010).
  CAS PubMed Google Scholar
• Talwalkar, J. A. et al. Magnetic resonance imaging of hepatic fibrosis: emerging clinical applications. Hepatology 47, 332–342 (2008).
  PubMed Google Scholar
• Bonekamp, S., Kamel, I., Solga, S. & Clark, J. Can imaging modalities diagnose and stage hepatic fibrosis and cirrhosis accurately? J. Hepatol. 50, 17–35 (2009).
  PubMed Google Scholar
• Taouli, B. et al. Diffusion-weighted MRI for quantification of liver fibrosis: preliminary experience. AJR Am. J. Roentgenol. 189, 799–806 (2007).
  PubMed Google Scholar
• Hagiwara, M. et al. Advanced liver fibrosis: diagnosis with 3D whole-liver perfusion MR imaging--initial experience. Radiology 246, 926–934 (2008).
  PubMed Google Scholar
• Barash, H. et al. Functional magnetic resonance imaging monitoring of pathological changes in rodent livers during hyperoxia and hypercapnia. Hepatology 48, 1232–1241 (2008).
  PubMed Google Scholar
• Fahey, B. J., Nightingale, K. R., Nelson, R. C., Palmeri, M. L. & Trahey, G. E. Acoustic radiation force impulse imaging of the abdomen: demonstration of feasibility and utility. Ultrasound Med. Biol. 31, 1185–1198 (2005).
  PubMed Google Scholar
• Friedrich-Rust, M. et al. Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography. Radiology 252, 595–604 (2009).
  PubMed Google Scholar
• Smith, J. O. & Sterling, R. K. Systematic review: Non-invasive methods of fibrosis analysis in chronic hepatitis C. Aliment. Pharmacol. Ther. 30, 557–576 (2009).
  CAS PubMed Google Scholar
• Smith, M. W. et al. Gene expression patterns that correlate with hepatitis C and early progression to fibrosis in liver transplant recipients. Gastroenterology 130, 179–187 (2006).
  CAS PubMed Google Scholar
• Leroy, V. et al. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J. Hepatol. 46, 775–782 (2007).
  PubMed Google Scholar
• Gressner, O. A., Weiskirchen, R. & Gressner, A. M. Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending between fiction and reality. J. Cell. Mol. Med. 11, 1031–1051 (2007).
  CAS PubMed Central PubMed Google Scholar
• Nunes, D. et al. Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. Am. J. Gastroenterol. doi: 10.1038/ajg.2009.746.
  Google Scholar
• Ngo, Y. et al. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin. Chem. 52, 1887–1896 (2006).
  CAS PubMed Google Scholar
• Mayo, M. J. et al. Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology 48, 1549–1557 (2008).
  PubMed Google Scholar
• Sebastiani, G. et al. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology 49, 1821–1827 (2009).
  PubMed Google Scholar
• Castera, L. et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 128, 343–350 (2005).
  PubMed Google Scholar
• Fontana, R. J. et al. Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis. Clin. Gastroenterol. Hepatol. 7, 219–226 (2009).
  CAS PubMed Google Scholar
• Nobili, V. et al. Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. Gastroenterology 136, 160–167 (2009).
  CAS PubMed Google Scholar
• de Ledinghen, V. et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J. Acquir. Immune Defic. Syndr. 41, 175–179 (2006).
  PubMed Google Scholar
• Sanchez-Conde, M. et al. Comparison of transient elastography and liver biopsy for the assessment of liver fibrosis in HIV/hepatitis C virus-coinfected patients and correlation with noninvasive serum markers. J. Viral Hepat. 17, 280–286 (2009).
  PubMed Google Scholar
• Berenguer, J. et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 50, 407–413 (2009).
  CAS PubMed Google Scholar
• Russo, M. W. et al. Early hepatic stellate cell activation is associated with advanced fibrosis after liver transplantation in recipients with hepatitis C. Liver Transpl. 11, 1235–1241 (2005).
  PubMed Google Scholar
• Armuzzi, A. et al. Review article: breath testing for human liver function assessment. Aliment. Pharmacol. Ther. 16, 1977–1996 (2002).
  CAS PubMed Google Scholar
• Petrolati, A. et al. 13C-methacetin breath test for monitoring hepatic function in cirrhotic patients before and after liver transplantation. Aliment. Pharmacol. Ther. 18, 785–790 (2003).
  CAS PubMed Google Scholar
• Ripoll, C. et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 133, 481–488 (2007).
  CAS PubMed Google Scholar
• Talwalkar, J. A. Antifibrotic therapies—emerging biomarkers as treatment end points. Nat. Rev. Gastroenterol. Hepatol. 7, 59–61 (2010).
  CAS PubMed Google Scholar
• Hold, G. L., Untiveros, P., Saunders, K. A. & El-Omar, E. M. Role of host genetics in fibrosis. Fibrogenesis Tissue Repair 2, 6 (2009).
  PubMed Central PubMed Google Scholar
• Weber, S., Gressner, O. A., Hall, R., Grunhage, F. & Lammert, F. Genetic determinants in hepatic fibrosis: from experimental models to fibrogenic gene signatures in humans. Clin. Liver Dis. 12, 747–757 (2008).
  PubMed Google Scholar
• Wasmuth, H. E. et al. The Marburg I variant (G534E) of the factor VII-activating protease determines liver fibrosis in hepatitis C infection by reduced proteolysis of platelet-derived growth factor BB. Hepatology 49, 775–780 (2009).
  CAS PubMed Google Scholar
• Asselah, T. et al. Genetics, genomics, and proteomics: implications for the diagnosis and the treatment of chronic hepatitis C. Semin. Liver Dis. 27, 13–27 (2007).
  CAS PubMed Google Scholar
• Huang, H. et al. A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology 46, 297–306 (2007).
  CAS PubMed Google Scholar
• Huang, H. et al. Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. Gastroenterology 130, 1679–1687 (2006).
  CAS PubMed Google Scholar
• Marcolongo, M. et al. A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. Hepatology 50, 1038–1044 (2009).
  CAS PubMed Google Scholar
• Wasmuth, H. E. et al. CC chemokine receptor 5 delta32 polymorphism in two independent cohorts of hepatitis C virus infected patients without hemophilia. J. Mol. Med. 82, 64–69 (2004).
  CAS PubMed Google Scholar
• Hillebrandt, S. et al. Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans. Nat. Genet. 37, 835–843 (2005).
  CAS PubMed Google Scholar
• Hung, T. M. et al. A novel nonsynonymous variant of matrix metalloproteinase-7 confers risk of liver cirrhosis. Hepatology 50, 1184–1193 (2009).
  CAS PubMed Google Scholar
• Freedman, N. D. et al. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology 50, 1360–1369 (2009).
  CAS PubMed Google Scholar
• Ruhl, C. E. & Everhart, J. E. Coffee and tea consumption are associated with a lower incidence of chronic liver disease in the United States. Gastroenterology 129, 1928–1936 (2005).
  PubMed Google Scholar
• Modi, A. A. et al. Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology 51, 201–209 (2010).
  CAS PubMed Google Scholar
• Chan, E. S. et al. Adenosine A(2A) receptors play a role in the pathogenesis of hepatic cirrhosis. Br. J. Pharmacol. 148, 1144–1155 (2006).
  CAS PubMed Central PubMed Google Scholar
• Chan, H. L. et al. Hepatitis B virus genotype C is associated with more severe liver fibrosis than genotype B. Clin. Gastroenterol. Hepatol. 7, 1361–1366 (2009).
  PubMed Google Scholar
• Bochud, P. Y. et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J. Hepatol. 51, 655–666 (2009).
  CAS PubMed Google Scholar
• Macias, J. et al. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology 50, 1056–1063 (2009).
  CAS PubMed Google Scholar
• Pinzani, M. & Vizzutti, F. Fibrosis and cirrhosis reversibility: clinical features and implications. Clin. Liver Dis. 12, 901–913 (2008).
  PubMed Google Scholar
• Ramachandran, P. & Iredale, J. P. Reversibility of liver fibrosis. Ann. Hepatol. 8, 283–291 (2009).
  PubMed Google Scholar
• Garcia-Tsao, G., Friedman, S., Iredale, J. & Pinzani, M. Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis. Hepatology 51, 1445–1449 (2010).
  PubMed Google Scholar
• Ghany, M. G. et al. Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology 138, 136–146 (2010).
  CAS PubMed Google Scholar
• Kazemi, F. et al. Liver stiffness measurement selects patients with cirrhosis at risk of bearing large oesophageal varices. J. Hepatol. 45, 230–235 (2006).
  PubMed Google Scholar
• Masuzaki, R. et al. Risk assessment of hepatocellular carcinoma in chronic hepatitis C patients by transient elastography. J. Clin. Gastroenterol. 42, 839–843 (2008).
  PubMed Google Scholar
• Nagula, S., Jain, D., Groszmann, R. J. & Garcia-Tsao, G. Histological–hemodynamic correlation in cirrhosis—a histological classification of the severity of cirrhosis. J. Hepatol. 44, 111–117 (2006).
  PubMed Google Scholar
• Iredale, J. P. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J. Clin. Invest. 117, 539–548 (2007).
  CAS PubMed Central PubMed Google Scholar
• Popov, Y., Patsenker, E., Fickert, P., Trauner, M. & Schuppan, D. Mdr2 (Abcb4)−/− mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. J. Hepatol. 43, 1045–1054 (2005).
  CAS PubMed Google Scholar
• Lichtman, S. N., Wang, J. & Clark, R. L. A microcholangiographic study of liver disease models in rats. Acad. Radiol. 2, 515–521 (1995).
  CAS PubMed Google Scholar
• Popov, Y. et al. Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies. J. Hepatol. 48, 453–464 (2008).
  CAS PubMed Google Scholar
• Friedman, S. L. Reversibility of hepatic fibrosis and cirrhosis--is it all hype? Nat. Clin. Pract. Gastroenterol. Hepatol. 4, 236–237 (2007).
  PubMed Google Scholar
• Ghiassi-Nejad, Z. & Friedman, S. L. Advances in antifibrotic therapy. Expert Rev. Gastroenterol. Hepatol. 2, 803–816 (2008).
  PubMed Central PubMed Google Scholar
• Rockey, D. C. Current and future anti-fibrotic therapies for chronic liver disease. Clin. Liver Dis. 12, 939–962 (2008).
  PubMed Central PubMed Google Scholar
• Popov, Y. & Schuppan, D. Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies. Hepatology 50, 1294–1306 (2009).
  CAS PubMed Google Scholar
• Schoemaker, M. H. et al. PDGF-receptor beta-targeted adenovirus redirects gene transfer from hepatocytes to activated stellate cells. Mol. Pharm. 5, 399–406 (2008).
  CAS PubMed Google Scholar
• Gonzalo, T. et al. Local inhibition of liver fibrosis by specific delivery of a PDGF kinase inhibitor to hepatic stellate cells. J. Pharmacol. Exp. Ther. 321, 856–865 (2007).
  CAS PubMed Google Scholar
• Friedman, S. L. Targeting siRNA to arrest fibrosis. Nat. Biotechnol. 26, 399–400 (2008).
  CAS PubMed Google Scholar
• Sato, Y. et al. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat. Biotechnol. 26, 431–442 (2008).
  CAS PubMed Google Scholar